Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Auto-Brewery Syndrome
NCT06083142Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2025
- Primary completion
- Aug 2029
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic fecal microbiota in Auto-brewery syndrome (ABS), sponsored by Massachusetts General Hospital. Primary endpoints: Treatment-Related Adverse Events at 6 months and Adequate dosing of FMT at 7 days. Started Feb 2025; status: active, not recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Auto-brewery syndrome (ABS)
Beyond the preview
Go deeper on NCT06083142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06083142.